• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    2/13/24 12:31:12 PM ET
    $BCYC
    $BIOL
    $BTAI
    $CADL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BCYC alert in real time by email

    Gainers

    • FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) shares rose 29.1% to $9.55 during Tuesday's regular session.
    • Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 24.82% to $1.74. The company's market cap stands at $50.1 million.
    • Bicycle Therapeutics (NASDAQ:BCYC) shares moved upwards by 23.42% to $21.5. The market value of their outstanding shares is at $810.8 million.
    • Envoy Medical (NASDAQ:COCH) stock rose 20.15% to $1.55. The market value of their outstanding shares is at $30.3 million.
    • Larimar Therapeutics (NASDAQ:LRMR) shares increased by 19.91% to $9.39. The market value of their outstanding shares is at $412.2 million.
    • BioXcel Therapeutics (NASDAQ:BTAI) shares moved upwards by 19.74% to $2.33. The market value of their outstanding shares is at $70.9 million.

    Losers

    • Sunshine Biopharma (NASDAQ:SBFM) stock declined by 65.8% to $0.07 during Tuesday's regular session. The company's market cap stands at $1.8 million.
    • Biolase (NASDAQ:BIOL) stock fell 65.11% to $0.16.
    • Sientra (NASDAQ:SIEN) stock fell 60.71% to $0.23. The company's market cap stands at $2.7 million.
    • G1 Therapeutics (NASDAQ:GTHX) shares declined by 54.25% to $2.05. The market value of their outstanding shares is at $106.2 million.
    • Renovaro Biosciences (NASDAQ:RENB) stock decreased by 44.52% to $1.86. The market value of their outstanding shares is at $125.3 million.
    • NanoString Technologies (NASDAQ:NSTG) stock fell 27.52% to $0.12. The market value of their outstanding shares is at $5.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCYC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCYC
    $BIOL
    $BTAI
    $CADL

    CompanyDatePrice TargetRatingAnalyst
    BioXcel Therapeutics Inc.
    $BTAI
    3/17/2026$17.00Buy
    Rodman & Renshaw
    Bicycle Therapeutics plc
    $BCYC
    11/24/2025$19.00Hold
    Truist
    Bicycle Therapeutics plc
    $BCYC
    10/31/2025$11.00Outperform → Sector Perform
    RBC Capital Mkts
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    Candel Therapeutics Inc.
    $CADL
    2/20/2025$25.00Buy
    Citigroup
    Candel Therapeutics Inc.
    $CADL
    2/19/2025$20.00Buy
    Canaccord Genuity
    More analyst ratings

    $BCYC
    $BIOL
    $BTAI
    $CADL
    SEC Filings

    View All

    Larimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

    3/19/26 7:04:23 AM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.

    SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)

    3/18/26 4:23:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Bicycle Therapeutics plc

    S-8 - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)

    3/17/26 4:05:35 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Mehta Vimal converted options into 383 shares, increasing direct ownership by 2% to 21,259 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    3/16/26 8:05:59 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 1% to 6,645 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    3/16/26 8:04:36 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Rodriguez Javier converted options into 68 shares, increasing direct ownership by 1% to 6,863 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    3/16/26 8:03:28 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00

    3/17/26 8:16:49 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Bicycle Therapeutics with a new price target

    Truist initiated coverage of Bicycle Therapeutics with a rating of Hold and set a new price target of $19.00

    11/24/25 8:33:30 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Bicycle Therapeutics from Outperform to Sector Perform and set a new price target of $11.00

    10/31/25 8:17:09 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA's review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved                                      

    3/19/26 7:00:00 AM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

    Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations of five abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. Presentation Details: Title: Preclinical assessment of BT5528 anti-tumor activity in cell-line-derived xenograft (CDX) models of head and neck squamous cell carcinoma (HNSCC) Type: Oral Presentation Session: Advanced Antibody, Conjugate, and Targeted Therapeutic Platforms Date and Time: Sunday, April 1

    3/18/26 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

    Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baseline PD-L1 tumor proportion scores (TPS) below 50% (a population typically less responsive to ICI), supporting the potential of aglatimagene to upregulate PD-L1 in the tumor microenvironment and convert

    3/17/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 4:31:16 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 11:21:53 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    * Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 7:46:04 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:41 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Frank E bought $25,000 worth of shares (5,000 units at $5.00), increasing direct ownership by 250% to 7,000 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:36 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    Leadership Updates

    Live Leadership Updates

    View All

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

    NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f

    9/2/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    Financials

    Live finance-specific insights

    View All

    Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

    In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4 key clinical outcomes (mFARS, FARS-ADL, 9-HPT, MFIS) observed after 1 year of nomlabofusp treatment could suggest potential for clinical benefit relative to a worsening in a FACOMS natural history st

    9/29/25 7:00:00 AM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

    BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss updates for the Company's nomlabofusp clinical development program including data from the ongoing long-term open label study for the treatment of Friedreich's ataxia on Monday, September 29, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, September 29, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (do

    9/28/25 5:00:00 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

    BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY At-Home

    8/27/25 8:00:16 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    $BIOL
    $BTAI
    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

    SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    11/14/24 5:46:12 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care